Genexine

Genexine EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Genexine (095700.KQ) as of Oct 19, 2026 is -36.07 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -59.48 B KRW — a change of -39.35% (higher).

EBITDA

-36.07 BKRW

YoY

-39.35%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Genexine is 2025 -36.07 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Genexine was 2024 -59.48 B KRW. It decreases by -39.35% higher compared to the previous year.

The Genexine EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-37.44 B KRW
Jan 1, 2019
-43.68 B KRW
Jan 1, 2020
-38.15 B KRW
Jan 1, 2021
-16.44 B KRW
Jan 1, 2022
-29.62 B KRW
Jan 1, 2023
-59.89 B KRW
Jan 1, 2024
-59.48 B KRW
Jan 1, 2025
-36.07 B KRW
The Genexine EBITDA history
YEAREBITDAYoY
-36.07 BKRW-39.35%
-59.48 BKRW-0.69%
-59.89 BKRW+102.19%
-29.62 BKRW+80.14%
-16.44 BKRW-56.90%
-38.15 BKRW-12.66%
-43.68 BKRW+16.65%
-37.44 BKRW+43.08%
-26.17 BKRW-12.99%
-30.08 BKRW-971.95%
3.45 BKRW+166.97%
1.29 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Genexine Stock analysis

What does Genexine do? Genexine Inc is a leading biotechnology company focused on developing therapies for serious diseases. The company was founded in Korea in 1999 and has since undergone impressive development. Genexine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genexine stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Genexine is -36.07 B KRW in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Genexine changed from -59.48 B KRW to -36.07 B KRW, representing a -39.35% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Genexine since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Genexine historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Genexine

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Genexine